Navigation Links
Misread heart muscle gene a new clue to risk of sudden cardiac death
Date:9/16/2013

Scientists have discovered that a drug which increases the risk of sudden cardiac death interacts with mistranslated protein-coding genes present in heart muscle.

The cardiac drug flecainide was developed to prevent and treat serious arrhythmias in the ventricles - the main pumps of the heart. These cause very rapid heart rates which can be lethal if unchecked. However in clinical trials, flecainide, and its sister molecule encainide, were reported to more than double the risk of sudden cardiac death.

Joint work by researchers in the Department of Chemistry and Warwick Medical School at the University of Warwick, and at the SEEK drug discovery group through subsidiary Tangent Reprofiling Limited, is now allowing insight into how cardiac death risk might be increased by these drugs. The method involves persuading viruses to provide a read-out on their surface of proteins related to human heart disease.

Genes that code for proteins, including those from the heart, may be read differently to normal - by starting at a different "letter" in the genetic code - these are called alternative reading frame (ARF) proteins, a bit like a very simple old cipher.

In experiments just published in the Royal Society of Chemistry journal Chemical Communications, the researchers show that flecainide appears to interact with just such an ARF protein, the "normal" version of which is crucial to heart function. This opens the way to further research that may illuminate the positive and negative elements of flecainide's action.

Paul Taylor, Associate Professor in Organic Chemistry, commented "Genes provide the code for cells to make proteins. This new research indicates that flecainide is able to interact with an unexpected translation of the gene coding for the protein - myosin regulatory light chain - a crucial component in the contraction of heart muscle fibres."

Associate Professor of Chemistry Andrew Marsh added "The work is particularly important as it represents a new way to uncover interactions of drugs such as flecainide with ARF proteins. The fuller biomedical significance of these unusual, 'mistranslated' proteins is only just becoming recognised."

Dr Suzanne Dilly, Head of Chemical Biology at SEEK, said " I am delighted to see publication of these important results, which were enabled by sharing of expertise and technology between an excellent academic team and our drug discovery group."

Professor of Clinical Pharmacology and Therapeutics Donald Singer said "Adverse effects of drugs can be very serious. Our work shows an unexpected consequence of adverse effects of a drug: providing clues to new causes for disease and new ideas for treatments. There is clear potential to apply these methods to understanding unexplained risks of other medicines".


'/>"/>

Contact: Paul Taylor
p.c.taylor@warwick.ac.uk
44-024-765-24375
University of Warwick
Source:Eurekalert

Related biology news :

1. Nymi by Bionym launches using your unique heartbeat to unlock your world
2. Your fingers pulse holds the key to your hearts health
3. Youthful stem cells from bone can heal the heart, Temple scientists report
4. Risk factors help predict outcomes for children with rare heart condition
5. Bacterial toxins cause deadly heart disease
6. Visualized heartbeat can trigger out-of-body experience
7. New study redefines how plaques grow in heart disease
8. Calcium linked to increased risk of heart disease and death in patients with kidney disease
9. A heart of gold
10. MS drug shows promise for preventing heart failure
11. Protein targeted for cancer drug development is essential for normal heart function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2016)... 12, 2016 WearablesResearch.com , a brand ... overview results from the Q1 wave of its quarterly ... was consumers, receptivity to a program where they would ... health insurance company. "We were surprised to ... Michael LaColla , CEO of Troubadour Research, "primarily ...
(Date:4/26/2016)... and LONDON , ... Finacle, part of EdgeVerve Systems, a product subsidiary ... Onegini today announced a partnership to integrate the ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... provide their customers enhanced security to access and ...
(Date:4/14/2016)... 2016 BioCatch ™, the ... announced the appointment of Eyal Goldwerger as ... Goldwerger,s leadership appointment comes at a time of ... deployment of its platform at several of the world,s ... discerns unique cognitive and physiological factors, is a winner ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... June 23, 2016 , ... ... announce the launch of their brand, UP4™ Probiotics, into Target stores nationwide. The ... is proud to add Target to its list of well-respected retailers. This list ...
(Date:6/23/2016)... , June 23, 2016 Houston Methodist ... the Cy-Fair Sports Association to serve as their ... agreement, Houston Methodist Willowbrook will provide sponsorship support, ... connectivity with association coaches, volunteers, athletes and families. ... the Cy-Fair Sports Association and to bring Houston ...
(Date:6/23/2016)... SAN FRANCISCO , June 23, 2016   ... it has secured $1 million in debt financing from ... to ramp up automation and to advance its drug ... for its new facility. "SVB has been ... goes beyond the services a traditional bank would provide," ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
Breaking Biology Technology: